Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1865, Issue 1, 2016, Pages 23-34

  Lahmar, Qods ^a,b   Keirsse, Jiri ^a,b   Laoui, Damya ^a,b   Movahedi, Kiavash ^a,b   Van Overmeire, Eva ^a,b   Van Ginderachter, Jo A ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Breast cancer; Glioma; Hepatocellular carcinoma; Kupffer cell; Lung cancer; Microglia; Monocyte derived macrophages; Pancreatic adenocarcinoma; Tissue resident macrophages; Tumor associated macrophages

Indexed keywords

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER GROWTH; CELLULAR DISTRIBUTION; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; INNATE IMMUNITY; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MACROPHAGE; MONOCYTE; NONHUMAN; ONTOGENY; PANCREAS CANCER; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; COMPARATIVE STUDY; CYTOLOGY; IMMUNOLOGY; NEOPLASM; PHYSIOLOGY;

ANIMALS; HUMANS; MACROPHAGES; MONOCYTES; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84958863725     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2015.06.009     Document Type: Article

References (184)

1. van Furth R., Cohn Z.A. The origin and kinetics of mononuclear phagocytes. J. Exp. Med. 1968, 128:415-435.
2. Schulz C., Gomez Perdiguero E., Chorro L., Szabo-Rogers H., Cagnard N., Kierdorf K., et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 2012, 336:86-90.
3. Perdiguero E.G., Klapproth K., Schulz C., Busch K., Azzoni E., Crozet L., et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 2014, 518:547-551.
4. Hoeffel G., Chen J., Lavin Y., Low D., Almeida F.F., See P., et al. C-myb(+) erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages. Immunity 2015, 42:665-678.
5. Guilliams M., De Kleer I., Henri S., Post S., Vanhoutte L., De Prijck S., et al. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. J. Exp. Med. 2013, 210:1977-1992.
6. Ginhoux F., Greter M., Leboeuf M., Nandi S., See P., Gokhan S., et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010, 330:841-845.
7. Hoeffel G., Wang Y., Greter M., See P., Teo P., Malleret B., et al. Adult Langerhans cells derive predominantly from embryonic fetal liver monocytes with a minor contribution of yolk sac-derived macrophages. J. Exp. Med. 2012, 209:1167-1181.
8. Yona S., Kim K.-W., Wolf Y., Mildner A., Varol D., Breker M., et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 2013, 38:79-91.
9. Hashimoto D., Chow A., Noizat C., Teo P., Beasley M.B., Leboeuf M., et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 2013, 38:792-804.
10. Bain C.C., Bravo-Blas A., Scott C.L., Gomez Perdiguero E., Geissmann F., Henri S., et al. Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. Nat. Immunol. 2014, 15:929-937.
11. Epelman S., Lavine K.J., Randolph G.J. Origin and functions of tissue macrophages. Immunity 2014, 41:21-35.
12. Epelman S., Lavine K.J., Beaudin A.E., Sojka D.K., Carrero J.A., Calderon B., et al. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity 2014, 40:91-104.
13. Molawi K., Wolf Y., Kandalla P.K., Favret J., Hagemeyer N., Frenzel K., et al. Progressive replacement of embryo-derived cardiac macrophages with age. J. Exp. Med. 2014, 211:2151-2158.
14. Bingle L., Brown N.J., Lewis C.E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 2002, 196:254-265.
15. Zhang Q., Liu L., Gong C., Shi H., Zeng Y., Wang X., et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One 2012, 7:e50946.
16. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66:605-612.
17. Qian B.-Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
18. Ruffell B., Affara N.I., Coussens L.M. Differential macrophage programming in the tumor microenvironment. Trends Immunol. 2012, 33:119-126.
19. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266.
20. Murdoch C., Muthana M., Coffelt S.B., Lewis C.E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 2008, 8:618-631.
21. Pollard J.W. Trophic macrophages in development and disease. Nat. Rev. Immunol. 2009, 9:259-270.
22. De Palma M., Lewis C.E. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013, 23:277-286.
23. Van Overmeire E., Laoui D., Keirsse J., Bonelli S., Lahmar Q., Van Ginderachter J.a STAT of the union: dynamics of distinct tumor-associated macrophage subsets governed by STAT1. Eur. J. Immunol. 2014, 44:2238-2242.
24. Gouon-Evans V., Rothenberg M.E., Pollard J.W. Postnatal mammary gland development requires macrophages and eosinophils. Development 2000, 127:2269-2282.
25. Gouon-Evans V., Lin E.Y., Pollard J.W. Requirement of macrophages and eosinophils and their cytokines/chemokines for mammary gland development. Breast Cancer Res. 2002, 4:155-164.
26. Ingman W.V., Wyckoff J., Gouon-Evans V., Condeelis J., Pollard J.W. Macrophages promote collagen fibrillogenesis around terminal end buds of the developing mammary gland. Dev. Dyn. 2006, 235:3222-3229.
27. Coussens L.M., Pollard J.W. Leukocytes in mammary development and cancer. Cold Spring Harb. Perspect. Biol. 2011, 3.
28. Wiktor-Jedrzejczak W., Bartocci A., Ferrante A.W., Ahmed-Ansari A., Sell K.W., Pollard J.W., et al. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:4828-4832.
29. Pollard J.W., Hennighausen L. Colony stimulating factor 1 is required for mammary gland development during pregnancy. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:9312-9316.
30. Van Nguyen A., Pollard J.W. Colony stimulating factor-1 is required to recruit macrophages into the mammary gland to facilitate mammary ductal outgrowth. Dev. Biol. 2002, 247:11-25.
31. Gyorki D.E., Asselin-Labat M.-L., van Rooijen N., Lindeman G.J., Visvader J.E. Resident macrophages influence stem cell activity in the mammary gland. Breast Cancer Res. 2009, 11:R62.
32. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, D. Forman, Global cancer statistics., CA. Cancer J. Clin. 61 (n.d.) 69-90.
33. DeSantis C., Siegel R., Bandi P., Jemal A. Breast cancer statistics. CA Cancer J. Clin. 2011, 61(n.d):409-418.
34. de Visser K.E., Eichten A., Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 2006, 6:24-37.
35. DeNardo D.G., Coussens L.M. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007, 9:212.
36. Ham M., Moon A. Inflammatory and microenvironmental factors involved in breast cancer progression. Arch. Pharm. Res. 2013, 36:1419-1431.
37. Noy R., Pollard J.W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014, 41:49-61.
38. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
39. Mantovani A., Marchesi F., Porta C., Sica A., Allavena P. Inflammation and cancer: breast cancer as a prototype. Breast 2007, 16(Suppl. 2):S27-S33.
40. Lin E.Y., Pollard J.W. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 2007, 67:5064-5066.
41. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23:549-555.
42. Laoui D., Movahedi K., Van Overmeire E., Van den Bossche J., Schouppe E., Mommer C., et al. Tumor-associated Macrophages in Breast Cancer: Distinct Subsets, Distinct Functions 2011, 861-867.
43. Bonapace L., Coissieux M.-M., Wyckoff J., Mertz K.D., Varga Z., Junt T., et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature 2014, 515:130-133.
44. Campbell M.J., Tonlaar N.Y., Garwood E.R., Huo D., Moore D.H., Khramtsov A.I., et al. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res. Treat. 2011, 128:703-711.
45. Tymoszuk P., Evens H., Marzola V., Wachowicz K., Wasmer M.-H., Datta S., et al. In situ proliferation contributes to accumulation of tumor-associated macrophages in spontaneous mammary tumors. Eur. J. Immunol. 2014, 44:2247-2262.
46. Franklin R.A., Liao W., Sarkar A., Kim M.V., Bivona M.R., Liu K., et al. The cellular and molecular origin of tumor-associated macrophages. Science 2014, 344:921-925.
47. De Palma M., Venneri M.A., Galli R., Sergi Sergi L., Politi L.S., Sampaolesi M., et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8:211-226.
48. Mazzieri R., Pucci F., Moi D., Zonari E., Ranghetti A., Berti A., et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011, 19:512-526.
49. Venneri M.A., De Palma M., Ponzoni M., Pucci F., Scielzo C., Zonari E., et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 2007, 109:5276-5285.
50. Nakasone E.S., Askautrud H.A., Kees T., Park J.-H., Plaks V., Ewald A.J., et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 2012, 21:488-503.
51. DeNardo D.G., Brennan D.J., Rexhepaj E., Ruffell B., Shiao S.L., Madden S.F., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011, 1:54-67.
52. Forget M.A., Voorhees J.L., Cole S.L., Dakhlallah D., Patterson I.L., Gross A.C., et al. Macrophage colony-stimulating factor augments Tie2-expressing monocyte differentiation, angiogenic function, and recruitment in a mouse model of breast cancer. PLoS One 2014, 9:e98623.
53. Egeblad M., Ewald A.J., Askautrud H.A., Truitt M.L., Welm B.E., Bainbridge E., et al. Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy. Dis. Model. Mech. 2008, 1:155-167.
54. Movahedi K., Laoui D., Gysemans C., Baeten M., Stangé G., Van den Bossche J., et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010, 70:5728-5739.
55. Ruffell B., Chang-Strachan D., Chan V., Rosenbusch A., Ho C.M.T., Pryer N., et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 2014, 26:623-637.
56. Casazza A., Laoui D., Wenes M., Rizzolio S., Bassani N., Mambretti M., et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 2013, 24:695-709.
57. Pucci F., Venneri M.A., Biziato D., Nonis A., Moi D., Sica A., et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 2009, 114:901-914.
58. Wyckoff J.B., Wang Y., Lin E.Y., Li J., Goswami S., Stanley E.R., et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007, 67:2649-2656.
59. Goswami S., Sahai E., Wyckoff J.B., Cammer M., Cox D., Pixley F.J., et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res. 2005, 65:5278-5283.
60. Robinson B.D., Sica G.L., Liu Y.-F., Rohan T.E., Gertler F.B., Condeelis J.S., et al. Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin. Cancer Res. 2009, 15:2433-2441.
61. Kedrin D., Gligorijevic B., Wyckoff J., Verkhusha V.V., Condeelis J., Segall J.E., et al. Intravital imaging of metastatic behavior through a mammary imaging window. Nat. Methods 2008, 5:1019-1021.
62. Toi M., Ueno T., Matsumoto H., Saji H., Funata N., Koike M., et al. Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer. Clin. Cancer Res. 1999, 5:1131-1137.
63. Remark R., Becker C., Gomez J.E., Damotte D., Dieu-Nosjean M.-C., Sautès-Fridman C., et al. The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. Am. J. Respir. Crit. Care Med. 2015, 191:377-390.
64. Jakubzick C., Gautier E.L., Gibbings S.L., Sojka D.K., Schlitzer A., Johnson T.E., et al. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity 2013, 39:599-610.
65. Gautier E.L., Shay T., Miller J., Greter M., Jakubzick C., Ivanov S., et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat. Immunol. 2012, 13:1118-1128.
66. Misharin A.V., Morales-Nebreda L., Mutlu G.M., Budinger G.R.S., Perlman H. Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. Am. J. Respir. Cell Mol. Biol. 2013, 49:503-510.
67. Shibata Y., Berclaz P.Y., Chroneos Z.C., Yoshida M., Whitsett J.A., Trapnell B.C. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 2001, 15:557-567.
68. Wang Y., Szretter K.J., Vermi W., Gilfillan S., Rossini C., Cella M., et al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat. Immunol. 2012, 13:753-760.
69. Bedoret D., Wallemacq H., Marichal T., Desmet C., Quesada Calvo F., Henry E., et al. Lung interstitial macrophages alter dendritic cell functions to prevent airway allergy in mice. J. Clin. Invest. 2009, 119:3723-3738.
70. Landsman L., Varol C., Jung S. Distinct differentiation potential of blood monocyte subsets in the lung. J. Immunol. 2007, 178:2000-2007.
71. Scott C.L., Henri S., Guilliams M. Mononuclear phagocytes of the intestine, the skin, and the lung. Immunol. Rev. 2014, 262:9-24.
72. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics. CA Cancer J. Clin. 1999, 49:8-31. (1).
73. Takanami I., Takeuchi K., Kodaira S. Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology 1999, 57:138-142.
74. Zhang B.C., Gao J., Wang J., Rao Z.G., Wang B.C., Gao J.F. Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med. Oncol. 2011, 28:1447-1452.
75. Chen J.J.W., Lin Y.-C., Yao P.-L., Yuan A., Chen H.-Y., Shun C.-T., et al. Tumor-associated macrophages: the double-edged sword in cancer progression. J. Clin. Oncol. 2005, 23:953-964.
76. Welsh T.J., Green R.H., Richardson D., Waller D.A., O'Byrne K.J., Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J. Clin. Oncol. 2005, 23:8959-8967.
77. Kim D.-W., Min H.S., Lee K.-H., Kim Y.J., Oh D.-Y., Jeon Y.K., et al. High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. Br. J. Cancer 2008, 98:1118-1124.
78. Dai F., Liu L., Che G., Yu N., Pu Q., Zhang S., et al. The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer 2010, 10:220.
79. Al-Shibli K., Al-Saad S., Donnem T., Persson M., Bremnes R.M., Busund L.-T. The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology 2009, 55:301-312.
80. Toomey D., Smyth G., Condron C., Kelly J., Byrne A.-M., Kay E., et al. Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: no association with prognosis identified in 3-year follow-up. Int. J. Cancer 2003, 103:408-412.
81. Carus A., Ladekarl M., Hager H., Pilegaard H., Nielsen P.S., Donskov F. Tumor-associated neutrophils and macrophages in non-small cell lung cancer: no immediate impact on patient outcome. Lung Cancer 2013, 81:130-137.
82. Kawai O., Ishii G., Kubota K., Murata Y., Naito Y., Mizuno T., et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008, 113:1387-1395.
83. Goldstraw P., Ball D., Jett J.R., Le Chevalier T., Lim E., Nicholson A.G., et al. Non-small-cell lung cancer. Lancet 2011, 378:1727-1740.
84. Bertram J.S., Janik P. Establishment of a cloned line of Lewis lung carcinoma cells adapted to cell culture. Cancer Lett. 1980, 11:63-73.
85. Laoui D., Van Overmeire E., Di Conza G., Aldeni C., Keirsse J., Morias Y., et al. Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Res. 2014, 74:24-30.
86. Sawanobori Y., Ueha S., Kurachi M., Shimaoka T., Talmadge J.E., Abe J., et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008, 111:5457-5466.
87. Cortez-Retamozo V., Etzrodt M., Newton A., Rauch P.J., Chudnovskiy A., Berger C., et al. Origins of tumor-associated macrophages and neutrophils. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:2491-2496.
88. Cortez-Retamozo V., Etzrodt M., Newton A., Ryan R., Pucci F., Sio S.W., et al. Angiotensin II drives the production of tumor-promoting macrophages. Immunity 2013, 38:296-308.
89. Movahedi K., Schoonooghe S., Laoui D., Houbracken I., Waelput W., Breckpot K., et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res. 2012, 72:4165-4177.
90. Zhang J., Cao J., Ma S., Dong R., Meng W., Ying M., et al. Tumor hypoxia enhances non-small cell lung cancer metastasis by selectively promoting macrophage M2 polarization through the activation of ERK signaling. Oncotarget 2014, 5:9664-9677.
91. Squadrito M.L., Pucci F., Magri L., Moi D., Gilfillan G.D., Ranghetti A., et al. miR-511-3p modulates genetic programs of tumor-associated macrophages. Cell Rep. 2012, 1:141-154.
92. Ohri C.M., Shikotra A., Green R.H., Waller D.A., Bradding P. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur. Respir. J. 2009, 33:118-126.
93. Ma J., Liu L., Che G., Yu N., Dai F., You Z. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 2010, 10:112.
94. Chung F.-T., Lee K.-Y., Wang C.-W., Heh C.-C., Chan Y.-F., Chen H.-W., et al. Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. Int. J. Cancer 2012, 131:E227-E235.
95. Zeni E., Mazzetti L., Miotto D., Lo Cascio N., Maestrelli P., Querzoli P., et al. Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur. Respir. J. 2007, 30:627-632.
96. Zhang B., Yao G., Zhang Y., Gao J., Yang B., Rao Z., et al. M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics (Sao Paulo) 2011, 66:1879-1886.
97. Ohtaki Y., Ishii G., Nagai K., Ashimine S., Kuwata T., Hishida T., et al. Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma. J. Thorac. Oncol. 2010, 5:1507-1515.
98. Hirayama S., Ishii G., Nagai K., Ono S., Kojima M., Yamauchi C., et al. Prognostic impact of CD204-positive macrophages in lung squamous cell carcinoma: possible contribution of Cd204-positive macrophages to the tumor-promoting microenvironment. J. Thorac. Oncol. 2012, 7:1790-1797.
99. J. Domagała-Kulawik, J. Guzman, U. Costabel, Immune cells in bronchoalveolar lavage in peripheral lung cancer-analysis of 140 cases., Respiration. 70 (n.d.) 43-8.
100. Pouniotis D.S., Plebanski M., Apostolopoulos V., McDonald C.F. Alveolar macrophage function is altered in patients with lung cancer. Clin. Exp. Immunol. 2006, 143:363-372.
101. Banaei-Bouchareb L., Gouon-Evans V., Samara-Boustani D., Castellotti M.C., Czernichow P., Pollard J.W., et al. Insulin cell mass is altered in Csf1op/Csf1op macrophage-deficient mice. J. Leukoc. Biol. 2004, 76:359-367.
102. Geutskens S.B., Otonkoski T., Pulkkinen M.-A., Drexhage H.A., Leenen P.J.M. Macrophages in the murine pancreas and their involvement in fetal endocrine development in vitro. J. Leukoc. Biol. 2005, 78:845-852.
103. Van Gassen N., Van Overmeire E., Leuckx G., Heremans Y., De Groef S., Cai Y., et al. Macrophage dynamics are regulated by local macrophage proliferation and monocyte recruitment in injured pancreas. Eur. J. Immunol. 2015, 45:1482-1493.
104. Van Gassen N., Staels W., Van Overmeire E., De Groef S., Sojoodi M., Heremans Y., et al. Concise review: macrophages: versatile gatekeepers during pancreatic β-cell development, injury, and regeneration. Stem Cells Transl. Med. 2015, 4:555-563.
105. Xiao X., Gaffar I., Guo P., Wiersch J., Fischbach S., Peirish L., et al. M2 macrophages promote beta-cell proliferation by up-regulation of SMAD7. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E1211-E1220.
106. Ryan D.P., Hong T.S., Bardeesy N. Pancreatic adenocarcinoma. N. Engl. J. Med. 2014, 371:1039-1049.
107. Bond-Smith G., Banga N., Hammond T.M., Imber C.J. Pancreatic adenocarcinoma. BMJ 2012, 344:e2476.
108. Wolfgang C.L., Herman J.M., Laheru D.A., Klein A.P., Erdek M.A., Fishman E.K., et al. Recent progress in pancreatic cancer. CA Cancer J. Clin. 2013, 63:318-348.
109. Clark C.E., Hingorani S.R., Mick R., Combs C., Tuveson D.A., Vonderheide R.H. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007, 67:9518-9527.
110. Liou G.-Y., Döppler H., Necela B., Krishna M., Crawford H.C., Raimondo M., et al. Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-κB and MMPs. J. Cell Biol. 2013, 202:563-577.
111. Liou G.-Y., Döppler H., Necela B., Edenfield B., Zhang L., Dawson D.W., et al. Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions. Cancer Discov. 2015, 5:52-63.
112. Liu C.-Y., Xu J.-Y., Shi X.-Y., Huang W., Ruan T.-Y., Xie P., et al. M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab. Investig. 2013, 93:844-854.
113. Weizman N., Krelin Y., Shabtay-Orbach A., Amit M., Binenbaum Y., Wong R.J., et al. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. Oncogene 2014, 33:3812-3819.
114. Mitchem J.B., Brennan D.J., Knolhoff B.L., Belt B.A., Zhu Y., Sanford D.E., et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013, 73:1128-1141.
115. Zhu Y., Knolhoff B.L., Meyer M.A., Nywening T.M., West B.L., Luo J., et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014, 74:5057-5069.
116. Cavel O., Shomron O., Shabtay A., Vital J., Trejo-Leider L., Weizman N., et al. Endoneurial macrophages induce perineural invasion of pancreatic cancer cells by secretion of GDNF and activation of RET tyrosine kinase receptor. Cancer Res. 2012, 72:5733-5743.
117. Kurahara H., Shinchi H., Mataki Y., Maemura K., Noma H., Kubo F., et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J. Surg. Res. 2011, 167:e211-e219.
118. Yoshikawa K., Mitsunaga S., Kinoshita T., Konishi M., Takahashi S., Gotohda N., et al. Impact of tumor-associated macrophages on invasive ductal carcinoma of the pancreas head. Cancer Sci. 2012, 103:2012-2020.
119. Ino Y., Yamazaki-Itoh R., Shimada K., Iwasaki M., Kosuge T., Kanai Y., et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br. J. Cancer 2013, 108:914-923.
120. Helm O., Held-Feindt J., Grage-Griebenow E., Reiling N., Ungefroren H., Vogel I., et al. Tumor-associated macrophages exhibit pro- and anti-inflammatory properties by which they impact on pancreatic tumorigenesis. Int. J. Cancer 2014, 135:843-861.
121. Karnevi E., Andersson R., Rosendahl A.H. Tumour-educated macrophages display a mixed polarisation and enhance pancreatic cancer cell invasion. Immunol. Cell Biol. 2014, 92:543-552.
122. Kurahara H., Takao S., Kuwahata T., Nagai T., Ding Q., Maeda K., et al. Clinical significance of folate receptor β-expressing tumor-associated macrophages in pancreatic cancer. Ann. Surg. Oncol. 2012, 19:2264-2271.
123. Rolny C., Mazzone M., Tugues S., Laoui D., Johansson I., Coulon C., et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011, 19:31-44.
124. Gironella M., Calvo C., Fernández A., Closa D., Iovanna J.L., Rosello-Catafau J., et al. Reg3β deficiency impairs pancreatic tumor growth by skewing macrophage polarization. Cancer Res. 2013, 73:5682-5694.
125. S.A. Arnold, L.B. Rivera, A.F. Miller, J.G. Carbon, S.P. Dineen, Y. Xie, et al., Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma., Dis. Model. Mech. 3 (n.d.) 57-72.
126. Hermano E., Meirovitz A., Meir K., Nussbaum G., Appelbaum L., Peretz T., et al. Macrophage polarization in pancreatic carcinoma: role of heparanase enzyme. J. Natl. Cancer Inst. 2014, 106.
127. Beatty G.L., Torigian D.A., Chiorean E.G., Saboury B., Brothers A., Alavi A., et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin. Cancer Res. 2013, 19:6286-6295.
128. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
129. Prinz M., Priller J. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat. Rev. Neurosci. 2014, 15:300-312.
130. Gomez Perdiguero E., Schulz C., Geissmann F. Development and homeostasis of "resident" myeloid cells: the case of the microglia. Glia 2013, 61:112-120.
131. Alliot F., Godin I., Pessac B. Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain. Brain Res. Dev. Brain Res. 1999, 117:145-152.
132. Prinz M., Priller J., Sisodia S.S., Ransohoff R.M. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat. Neurosci. 2011, 14:1227-1235.
133. Hickey W.F., Vass K., Lassmann H. Bone marrow-derived elements in the central nervous system: an immunohistochemical and ultrastructural survey of rat chimeras. J. Neuropathol. Exp. Neurol. 1992, 51:246-256.
134. Hickey W.F., Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 1988, 239:290-292.
135. Yamasaki R., Lu H., Butovsky O., Ohno N., Rietsch A.M., Cialic R., et al. Differential roles of microglia and monocytes in the inflamed central nervous system. J. Exp. Med. 2014, 211:1533-1549.
136. Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308:1314-1318.
137. Tremblay M.-È., Stevens B., Sierra A., Wake H., Bessis A., Nimmerjahn A. The role of microglia in the healthy brain. J. Neurosci. 2011, 31:16064-16069.
138. Salter M.W., Beggs S. Sublime microglia: expanding roles for the guardians of the CNS. Cell 2014, 158:15-24.
139. Kleihues P., Soylemezoglu F., Schäuble B., Scheithauer B.W., Burger P.C. Histopathology, classification, and grading of gliomas. Glia 1995, 15:211-221.
140. Omuro A., DeAngelis L.M. Glioblastoma and other malignant gliomas: a clinical review. JAMA 2013, 310:1842-1850.
141. Glass R., Synowitz M. CNS macrophages and peripheral myeloid cells in brain tumours. Acta Neuropathol. 2014, 128:347-362.
142. Komohara Y., Ohnishi K., Kuratsu J., Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J. Pathol. 2008, 216:15-24.
143. Müller A., Brandenburg S., Turkowski K., Müller S., Vajkoczy P. Resident microglia, and not peripheral macrophages, are the main source of brain tumor mononuclear cells. Int. J. Cancer 2015, 137:278-288.
144. Prinz M., Mildner A. Microglia in the CNS: immigrants from another world. Glia 2011, 59:177-187.
145. Butovsky O., Jedrychowski M.P., Moore C.S., Cialic R., Lanser A.J., Gabriely G., et al. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat. Neurosci. 2014, 17:131-143.
146. Hickman S.E., Kingery N.D., Ohsumi T.K., Borowsky M.L., Wang L., Means T.K., et al. The microglial sensome revealed by direct RNA sequencing. Nat. Neurosci. 2013, 16:1896-1905.
147. Pong W.W., Walker J., Wylie T., Magrini V., Luo J., Emnett R.J., et al. F11R is a novel monocyte prognostic biomarker for malignant glioma. PLoS One 2013, 8:e77571.
148. Pyonteck S.M., Akkari L., Schuhmacher A.J., Bowman R.L., Sevenich L., Quail D.F., et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 2013, 19:1264-1272.
149. Markovic D.S., Vinnakota K., Chirasani S., Synowitz M., Raguet H., Stock K., et al. Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:12530-12535.
150. Zhai H., Heppner F.L., Tsirka S.E. Microglia/macrophages promote glioma progression. Glia 2011, 59:472-485. 10.1002/glia.21117.
151. Villeneuve J., Tremblay P., Vallières L. Tumor necrosis factor reduces brain tumor growth by enhancing macrophage recruitment and microcyst formation. Cancer Res. 2005, 65:3928-3936.
152. Galarneau H., Villeneuve J., Gowing G., Julien J.-P., Vallières L. Increased glioma growth in mice depleted of macrophages. Cancer Res. 2007, 67:8874-8881.
153. Szulzewsky F., Pelz A., Feng X., Synowitz M., Markovic D., Langmann T., et al. Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1. PLoS One 2015, 10:e0116644.
154. Durafourt B.A., Moore C.S., Zammit D.A., Johnson T.A., Zaguia F., Guiot M.-C., et al. Comparison of polarization properties of human adult microglia and blood-derived macrophages. Glia 2012, 60:717-727.
155. Zhou W., Ke S.Q., Huang Z., Flavahan W., Fang X., Paul J., et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat. Cell Biol. 2015, 17:170-182.
156. Sarkar S., Döring A., Zemp F.J., Silva C., Lun X., Wang X., et al. Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells. Nat. Neurosci. 2014, 17:46-55.
157. Sliwa M., Markovic D., Gabrusiewicz K., Synowitz M., Glass R., Zawadzka M., et al. The invasion promoting effect of microglia on glioblastoma cells is inhibited by cyclosporin A. Brain 2007, 130:476-489.
158. Gabrusiewicz K., Ellert-Miklaszewska A., Lipko M., Sielska M., Frankowska M., Kaminska B. Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PLoS One 2011, 6:e23902.
159. De Palma M., Mazzieri R., Politi L.S., Pucci F., Zonari E., Sitia G., et al. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 2008, 14:299-311.
160. Jenne C.N., Kubes P. Immune surveillance by the liver. Nat. Immunol. 2013, 14:996-1006.
161. Sieweke M.H., Allen J.E. Beyond stem cells: self-renewal of differentiated macrophages. Science 2013, 342:1242974.
162. Kolios G., Valatas V., Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. World J. Gastroenterol. 2006, 12:7413-7420.
163. Tacke F., Zimmermann H.W. Macrophage heterogeneity in liver injury and fibrosis. J. Hepatol. 2014, 60:1090-1096.
164. Capece D., Fischietti M., Verzella D., Gaggiano A., Cicciarelli G., Tessitore A., et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed. Res. Int. 2013, 2013:187204.
165. Vucur M., Roderburg C., Bettermann K., Tacke F., Heikenwalder M., Trautwein C., et al. Mouse models of hepatocarcinogenesis: what can we learn for the prevention of human hepatocellular carcinoma?. Oncotarget 2010, 1:373-378.
166. Kang T.-W., Yevsa T., Woller N., Hoenicke L., Wuestefeld T., Dauch D., et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011, 479:547-551.
167. Maeda S., Kamata H., Luo J.-L., Leffert H., Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005, 121:977-990.
168. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
169. Wu J., Li J., Salcedo R., Mivechi N.F., Trinchieri G., Horuzsko A. The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma. Cancer Res. 2012, 72:3977-3986.
170. Schneider C., Teufel A., Yevsa T., Staib F., Hohmeyer A., Walenda G., et al. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut 2012, 61:1733-1743.
171. Wan S., Zhao E., Kryczek I., Vatan L., Sadovskaya A., Ludema G., et al. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology 2014, 147:1393-1404.
172. Wu K., Kryczek I., Chen L., Zou W., Welling T.H. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res. 2009, 69:8067-8075.
173. Kuang D.-M., Zhao Q., Peng C., Xu J., Zhang J.-P., Wu C., et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 2009, 206:1327-1337.
174. Matsubara T., Kanto T., Kuroda S., Yoshio S., Higashitani K., Kakita N., et al. TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. Hepatology 2013, 57:1416-1425.
175. Yang W., Lu Y., Xu Y., Xu L., Zheng W., Wu Y., et al. Estrogen represses hepatocellular carcinoma (HCC) growth via inhibiting alternative activation of tumor-associated macrophages (TAMs). J. Biol. Chem. 2012, 287:40140-40149.
176. Yeung O.W.H., Lo C.-M., Ling C.-C., Qi X., Geng W., Li C.-X., et al. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. J. Hepatol. 2015, 62:607-616.
177. Yan W., Liu X., Ma H., Zhang H., Song X., Gao L., et al. Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages. Gut 2015, (e-pub ahead of print).
178. Zhou J., Ding T., Pan W., Zhu L.-Y., Li L., Zheng L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int. J. Cancer 2009, 125:1640-1648.
179. Kuang D.-M., Peng C., Zhao Q., Wu Y., Zhu L.-Y., Wang J., et al. Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients. J. Immunol. 2010, 185:1544-1549.
180. Kuang D.-M., Peng C., Zhao Q., Wu Y., Chen M.-S., Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 2010, 51:154-164.
181. Budhu A., Forgues M., Ye Q.-H., Jia H.-L., He P., Zanetti K.A., et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006, 10:99-111.
182. Ruffell B., Au A., Rugo H.S., Esserman L.J., Hwang E.S., Coussens L.M. Leukocyte composition of human breast cancer. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:2796-2801.
183. Chittezhath M., Dhillon M.K., Lim J.Y., Laoui D., Shalova I.N., Teo Y.L., et al. Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression. Immunity 2014, 41:815-829.
184. Ji J., Zhang G., Sun B., Yuan H., Huang Y., Zhang J., et al. The frequency of tumor-infiltrating Tie-2-expressing monocytes in renal cell carcinoma: its relationship to angiogenesis and progression. Urology 2013, 82. (974.e9-13).